Organon [OGN] vs Eli Lilly and [LLY] Detailed Stock Comparison
Organon
NYSE
Loading...
Eli Lilly and
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Organon wins in 9 metrics, Eli Lilly and wins in 11 metrics, with 0 ties. Eli Lilly and appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Organon | Eli Lilly and | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 3.44 | 45.00 | Organon |
| Price-to-Book Ratio | 3.28 | 33.86 | Organon |
| Debt-to-Equity Ratio | 1,213.64 | 217.89 | Eli Lilly and |
| PEG Ratio | -0.13 | 0.49 | Organon |
| EV/EBITDA | 6.39 | 26.96 | Organon |
| Profit Margin (TTM) | 11.15% | 25.91% | Eli Lilly and |
| Operating Margin (TTM) | 21.08% | 45.81% | Eli Lilly and |
| EBITDA Margin (TTM) | 21.08% | 45.81% | Eli Lilly and |
| Return on Equity | 159.64% | 86.29% | Organon |
| Return on Assets (TTM) | 6.62% | 16.55% | Eli Lilly and |
| Free Cash Flow (TTM) | $588.00M | $414.30M | Organon |
| Dividend Yield | 8.50% | 0.52% | Organon |
| 1-Year Return | -58.50% | -25.50% | Eli Lilly and |
| Price-to-Sales Ratio (TTM) | 0.38 | 11.61 | Organon |
| Enterprise Value | $10.71B | $667.81B | Eli Lilly and |
| EV/Revenue Ratio | 1.71 | 12.54 | Organon |
| Gross Profit Margin (TTM) | 54.83% | 84.27% | Eli Lilly and |
| Revenue per Share (TTM) | $24 | $59 | Eli Lilly and |
| Earnings per Share (Diluted) | $2.69 | $15.33 | Eli Lilly and |
| Beta (Stock Volatility) | 0.57 | 0.44 | Eli Lilly and |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Organon vs Eli Lilly and Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Organon | 1.62% | -1.17% | -1.80% | 10.08% | -40.09% | -37.97% |
| Eli Lilly and | 0.26% | 3.71% | -6.87% | -2.09% | -18.76% | -8.77% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Organon | -58.50% | -68.74% | -72.09% | -72.09% | -72.09% | -72.09% |
| Eli Lilly and | -25.50% | 124.94% | 381.76% | 753.25% | 1,975.50% | 1,229.00% |
Performance & Financial Health Analysis: Organon vs Eli Lilly and
| Metric | OGN | LLY |
|---|---|---|
| Market Information | ||
| Market Cap | $2.41B | $618.46B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 4,624,446 | 9,239,525 |
| 90 Day Avg. Volume | 4,369,692 | 5,536,438 |
| Last Close | $9.43 | $711.68 |
| 52 Week Range | $8.01 - $23.10 | $623.78 - $972.53 |
| % from 52W High | -59.18% | -26.82% |
| All-Time High | $39.47 (Feb 28, 2022) | $972.53 (Aug 19, 2024) |
| % from All-Time High | -76.11% | -26.82% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.38% |
| Quarterly Earnings Growth | -0.26% | 0.91% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.26% |
| Operating Margin (TTM) | 0.21% | 0.46% |
| Return on Equity (TTM) | 1.60% | 0.86% |
| Debt to Equity (MRQ) | 1,213.64 | 217.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.82 | $20.38 |
| Cash per Share (MRQ) | $2.30 | $3.95 |
| Operating Cash Flow (TTM) | $826.00M | $10.94B |
| Levered Free Cash Flow (TTM) | $321.12M | $-2,265,437,440 |
| Dividends | ||
| Last 12-Month Dividend Yield | 8.50% | 0.52% |
| Last 12-Month Dividend | $0.84 | $4.10 |
Valuation & Enterprise Metrics Analysis: Organon vs Eli Lilly and
| Metric | OGN | LLY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 3.44 | 45.00 |
| Forward P/E | 2.19 | 30.45 |
| PEG Ratio | -0.13 | 0.49 |
| Price to Sales (TTM) | 0.38 | 11.61 |
| Price to Book (MRQ) | 3.28 | 33.86 |
| Market Capitalization | ||
| Market Capitalization | $2.41B | $618.46B |
| Enterprise Value | $10.71B | $667.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.71 | 12.54 |
| Enterprise to EBITDA | 6.39 | 26.96 |
| Risk & Other Metrics | ||
| Beta | 0.57 | 0.44 |
| Book Value per Share (MRQ) | $2.82 | $20.38 |
Financial Statements Comparison: Organon vs Eli Lilly and
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OGN | LLY |
|---|---|---|
| Revenue/Sales | $1.51B | $12.73B |
| Cost of Goods Sold | $672.00M | $2.22B |
| Gross Profit | $841.00M | $10.50B |
| Research & Development | $96.00M | $2.73B |
| Operating Income (EBIT) | $325.00M | $5.41B |
| EBITDA | $397.00M | $5.92B |
| Pre-Tax Income | $101.00M | $3.46B |
| Income Tax | $14.00M | $696.80M |
| Net Income (Profit) | $87.00M | $2.76B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OGN | LLY |
|---|---|---|
| Cash & Equivalents | $547.00M | $3.09B |
| Total Current Assets | $4.37B | $41.26B |
| Total Current Liabilities | $2.62B | $30.07B |
| Long-Term Debt | $8.94B | $34.50B |
| Total Shareholders Equity | $542.00M | $15.85B |
| Retained Earnings | $1.03B | $15.10B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OGN | LLY |
|---|---|---|
| Operating Cash Flow | $13.00M | $4.88B |
| Capital Expenditures | N/A | $-1.51B |
| Free Cash Flow | $-22.00M | $-1.60B |
| Debt Repayment | $-93.00M | N/A |
| Common Stock Repurchase | N/A | $-1.20B |
Short Interest & Institutional Ownership Analysis
| Metric | OGN | LLY |
|---|---|---|
| Shares Short | 15.01M | 7.17M |
| Short Ratio | 4.10 | 2.20 |
| Short % of Float | 0.08% | 0.01% |
| Average Daily Volume (10 Day) | 4,624,446 | 9,239,525 |
| Average Daily Volume (90 Day) | 4,369,692 | 5,536,438 |
| Shares Outstanding | 257.80M | 897.54M |
| Float Shares | 258.73M | 895.44M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.85% | 0.84% |
Dividend Analysis & Yield Comparison: Organon vs Eli Lilly and
| Metric | OGN | LLY |
|---|---|---|
| Last 12-Month Dividend | $0.84 | $4.10 |
| Last 12-Month Dividend Yield | 8.50% | 0.52% |
| 3-Year Avg Annual Dividend | $1.03 | $4.02 |
| 3-Year Avg Dividend Yield | 1.46% | 0.22% |
| 3-Year Total Dividends | $3.08 | $12.05 |
| Ex-Dividend Date | Feb 24, 2025 | Feb 14, 2025 |